U.S. probes neurological problems, Sanofi vaccine


  • World Premium
  • Saturday, 01 Oct 2005

WASHINGTON (Reuters) - U.S. officials are investigating if a Sanofi-Aventis meningitis vaccine may have caused five cases of a rare neurological disorder that can paralyze its victims, the government announced on Friday. 

The patients -- all 17 or 18 years old -- developed Guillain-Barre Syndrome, or GBS, after receiving Sanofi's Menactra vaccine, which was approved for sale in January. All are recovering or have recovered, officials said. 

Article type: metered
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights
   

Next In World

Few Europeans want a return to 9-5 at office after pandemic, survey shows Premium
UNICEF warns of malnutrition and disease risk for migrant children in Mexican camp Premium
Burkina Faso president fires PM amid security crisis Premium
Australia deputy PM tests positive for COVID-19 in Washington Premium
Canada's Omicron travel ban disrupts residents heading home Premium
Finland's PM apologises for not isolating after night club photo surfaces Premium
U.N. suspends food distribution in two towns in Ethiopia after looting Premium
Johnson imposes COVID-19 'Plan B' in England to contain Omicron Premium
Act now to curb Omicron's spread, WHO's Tedros tells world Premium
Saudi crown prince on first visit to Qatar since Gulf row resolved Premium

Others Also Read


Vouchers